The Illumina study will focus on the transfer of a single genetically tested embryo, hopefully increasing the success rate of in vitro fertilization, while eliminating the risks and occurrence of a multiple gestational pregnancy.
Bloomfield Hills, Michigan (PRWEB) October 19, 2015
IVF Michigan Fertility Center has been selected to be a major site of the “Single Embryo TrAnsfeR of Euploid Embryo” (STAR) study sponsored by Illumina. This study will involve preimplantation genetic screening of embryos generated during in vitro fertilization.
During the study, randomly selected patients that are undergoing IVF treatment will be offered genetic testing for most or all of their embryos. The goal of preimplantation genetic testing is to increase the cumulative pregnancy rates, a common concern for patients undergoing IVF treatment. This test will also reduce the risks of miscarriages and some birth defects related to genetic imbalances, such as Down syndrome.
Infertility currently affects approximately 12 percent of the U.S. population, but that rate is rising due to a variety of medical and cultural factors. To counter the rising rates of infertility, patients have turned to assisted reproductive technologies, such as in vitro fertilization (IVF), as the best, most cost-effective option. In IVF treatment, fertility specialists will often transfer more than one embryo during treatment to increase the chances of pregnancy. IVF Michigan has earned one of the highest success rates for IVF treatment using no more than two embryos at a time in women younger than 40 years of age, which reduces the potential risk of twins.
According to the study's Principal Investigator and IVF Michigan's President, Dr. F. Nicholas Shamma, “the Illumina study will focus on the transfer of a single genetically tested embryo, hopefully increasing the success rate of in vitro fertilization, while eliminating the risks and occurrence of a multiple gestational pregnancy.”
Illumina is the largest company worldwide that provides sequencing solutions for genetic analysis. It offers innovative technologies and treatment methods with an emphasis on human genomes. Scientists from Illumina are dedicated to their research of human DNA in order to make breakthroughs in healthcare and other medical and technological advances. Their discoveries have been pivotal in understanding illnesses and developing breakthrough treatment methods for these health abnormalities.
The Illumina study will be performed by IVF Michigan’s fertility experts, Dr. Shamma and Dr. Ahmad O. Hammoud, and it will be of no additional cost to the patients. This study will be available in IVF Michigan’s fertility clinics located in Bloomfield Hills, Dearborn, Saginaw, Ann Arbor, and Toledo. For more information regarding the Illumina study or to set up an appointment at IVF Michigan, call the toll free number 855-952-9600, or visit http://www.ivf-mi.com.